{
    "nctId": "NCT01936064",
    "briefTitle": "The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients",
    "officialTitle": "A Prospective Phase II Randomized, Blinded Study to Demonstrate the Effectiveness of Jobelyn for the Treatment of Breast Cancer Patients.",
    "overallStatus": "UNKNOWN",
    "conditions": "Haematological Abnormality",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Natural Killer Cells Expression",
    "eligibilityCriteria": "Inclusion Criteria:\n\nWomen with histologically confirmed breast cancer who had undergone complete or segmental mastectomy plus axillary node dissection were included\n\nExclusion Criteria:\n\nPatients were excluded if they had distant metastases residual disease in the breast or axilla other serious medical illnesses, or a previous cancer. Women considering pregnancy or using hormones were excluded\n\nPatients who refuse to sign consent form",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}